XNCR
USDXencor Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$14.340
Máximo
$14.340
Mínimo
$13.620
Volumen
0.91M
Fundamentos de la Empresa
Capitalización de Mercado
972.6M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.15M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Barclays Upgrades Xencor to Overweight, Raises Price Target to $23
Barclays analyst Etzer Darout upgrades Xencor from Underweight to Overweight and raises the price target from $6 to $23.
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $18
RBC Capital analyst Leonid Timashev maintains Xencor with a Outperform and raises the price target from $15 to $18.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.